Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06152276 Not yet recruiting - Colorectal Cancer Clinical Trials

SafeHeal Diverting Ileostomy Pivotal Study

SH-SOC23
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

This SafeHeal study is designed to assess the overall safety of the low anterior resection (LAR) standard of care cancer treatment by establishing a definition of major complications. The current literature on standard of care reports adverse events/complications but does not provide a single endpoint that can be used to compare the safety of LAR cancer treatment to alternative therapies or treatments. This study will allow for the establishment of a new single safety endpoint for LAR standard of care cancer treatment.

NCT ID: NCT06145230 Not yet recruiting - Colorectal Cancer Clinical Trials

A Cross-sectional Survey of Colorectal Cancer Patients in Different Age Groups

Start date: December 1, 2023
Phase:
Study type: Observational

This study will help to determine the main clinical symptom differences between patients of different ages, discover the family genetic predisposition of patients of different ages, and obtain the differences in pathological characteristics of patients of different ages, so as to provide help and basis for more accurate and earlier prevention and treatment of colorectal cancer.

NCT ID: NCT06137248 Not yet recruiting - Colorectal Cancer Clinical Trials

Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption

ROSANNA
Start date: February 2024
Phase: Phase 2
Study type: Interventional

This study will investigate whether short-term daily energy drink consumption results in an increase in hydrogen sulfide-producing bacteria in adults 18-40 years old.

NCT ID: NCT06136026 Not yet recruiting - Colorectal Cancer Clinical Trials

Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer

Start date: December 1, 2023
Phase:
Study type: Observational

This is a nationwide cohort study on integrated traditional Chinese and Western medicine for colorectal cancer. The aim is to elucidate the distribution patterns of TCM syndromes in colorectal cancer and colorectal adenoma, reveal the relationship between TCM syndromes and diagnosis, prognosis, and prognosis. Based on biological samples, a phenotypic omics study of TCM syndromes in colorectal cancer and colorectal adenoma is conducted.

NCT ID: NCT06134765 Not yet recruiting - Colorectal Cancer Clinical Trials

Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer

Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

A multi-cohort, open-label, multicenter exploratory clinical study of Bemalenograstim alfa for the prevention of reduced absolute neutrophil count(ANC) in patients with colorectal cancer/pancreatic cancer following a bi-weekly chemotherapy regimen.A total of 89 patients are planned to be enrolled.

NCT ID: NCT06128785 Not yet recruiting - Colorectal Cancer Clinical Trials

Electroacupuncture (EA) Promotes Gastrointestinal Functional Recovery After Radical Colorectal Cancer Surgery

Start date: November 6, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to verify the efficacy of electroacupuncture in accelerating the recovery of gastrointestinal function after colorectal cancer surgery. The main questions it aims to answer are: - Whether electroacupuncture can accelerate the recovery of gastrointestinal function in patients after colorectal cancer surgery. - Whether electroacupuncture intervention is safe for postoperative colorectal cancer patients. Participants will be randomized into 3 groups: The conventional control group will receive postoperative rehydration and nutritional support, correction of acid-base imbalance and electrolyte disturbance, anti-infection, hemostasis and other symptomatic treatments. In the electroacupuncture group, acupuncture will be performed within 6 hours after surgery on the basis of the conventional control group. Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37). Both after obtaining Qi, and unilaterally connected to the electroacupuncture instrument for electrical stimulation, the current frequency is continuous wave 5 Hz, the intensity of stimulation was as the patient tolerated, each time lasting 30 min. Acupuncture stimulation was given every 12 h. The course of treatment was terminated postoperatively until the fourth postoperative day (d0-d4) or until the patient showed the first postoperative anal exhaust or continued until the fourth day. The sham acupuncture group will based on the conventional control group, using a blunt-tipped needle tip that do not pierce the adhesive pad.

NCT ID: NCT06125145 Not yet recruiting - Breast Cancer Clinical Trials

Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study

GAP
Start date: February 7, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test a new way to help older adults who have had cancer. The researchers want to see if a program that assesses participants health and aging is achievable and makes a difference. A community health worker/promotora de salud will assess their health and provide coaching to help them feel better. This is important because older adults with cancer often have other health issues that are not addressed after completing treatment. The researchers want to make sure they get the care they need.

NCT ID: NCT06124729 Not yet recruiting - Colorectal Cancer Clinical Trials

Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases

Start date: December 2023
Phase:
Study type: Observational

Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases - a Single-center, Single-arm, Open-label Clinical Trail.

NCT ID: NCT06118060 Not yet recruiting - Colorectal Cancer Clinical Trials

Acupressure on Postoperative Ileus in Patients With Colorectal Cancer Surgery

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about acupressure in patients with colorectal cancer surgery. The main questions it aims to answer are: - whether acupressure can improve the motility of vagus nerve in patients after colorectal cancer surgery - whether acupressure can reduce the inflammatory response of the body - whether acupressure can reduce the incidence of gastrointestinal paralysis in patients after colorectal cancer surgery Participants will receive acupressure at ST36 twice daily starting from the first day after surgery and lasting for five days. Researchers will compare usual care group to see if acupressure has those above effects.

NCT ID: NCT06105021 Not yet recruiting - Colorectal Cancer Clinical Trials

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Start date: December 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients need to be positive for HLA-A*11:01. The purpose of this study is to find the best dose of AFNT 211 that is safe and can shrink tumors in patients. AFNT-211 is an investigational therapy and this is the first time that AFNT-211 is administered to patients. AFNT-211 is an autologous T cell product which means that it is made from a patient's own T cells. These cells are engineered and grown to recognize the KRAS G12V protein on the cell surface of cancer cells. AFNT-211 is infused into patients after a short course of chemotherapy. Patients will frequently visit the study site. The doctors there will regularly check the size of the cancer and the patient's health. They will also take note of any unwanted effects. Patients may continue in this study for as long as they benefit from the treatment.